Stereotactic Ablative Radiotherapy (SABR) Quality and Survival of Patients with Head and Neck Cancer: a post-hoc analysis of the GORTEC 2014-04 "OMET" Randomised Phase 2 Trial.

Fiche publication

Date publication

juillet 2025

Journal

International journal of radiation oncology, biology, physics

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi , Mr FALCOZ Antoine

Tous les auteurs :
Maury P, Sayous Y, Marnaoui R, Loiseau C, Khalladi N, Sun XS, Bourhis J, Vernerey D, Falcoz A, Thariat J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40714135

Résumé

the xxx trial showed prolonged survival with multisite stereotactic ablative radiotherapy (SABR) in oligometastatic head and neck cancer patients. However, deviations from radiotherapy protocol can be a confounding factor in clinical trials. The impact of SABR quality assurance by individual case review (ICR) of protocol deviations and quality metrics on survival and local control at SABR-treated oligometastases was assessed.